Cargando…

1238. Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States

BACKGROUND: Enterobacter spp. are part of the ESKAPE pathogens that have been recognized as a threat to human health. Among this genus, E. cloacae species complex (ECL) is the most common species that causes human infections. ECL can develop resistance to ß-lactams and other antimicrobial classes du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castanheira, Mariana, Streit, Jennifer M, Sader, Helio S, Shortridge, Dee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643822/ http://dx.doi.org/10.1093/ofid/ofab466.1430

Ejemplares similares

26. in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism
por: Castanheira, Mariana, et al.
Publicado: (2020)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates
por: Castanheira, Mariana, et al.
Publicado: (2021)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
por: Carvalhaes, Cecilia G., et al.
Publicado: (2020)

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
por: Shortridge, Dee, et al.
Publicado: (2022)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023)

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
por: Castanheira, Mariana, et al.
Publicado: (2023)

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States (US) Medical Centers (2013–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents
por: Sader, Helio S, et al.
Publicado: (2021)

Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021)

1218. Activity of Meropenem-Vaborbactam and Comparator Agents Against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation
por: Castanheira, Mariana, et al.
Publicado: (2023)

Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole-Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents
por: Castanheira, Mariana, et al.
Publicado: (2017)

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19)
por: Shortridge, Dee, et al.
Publicado: (2021)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

1589. Activity of Meropenem-Vaborbactam and Comparators against Globally Disseminated Klebsiella pneumoniae Sequence Type 258
por: Shorttidge, Dee, et al.
Publicado: (2020)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
por: Castanheira, Mariana, et al.
Publicado: (2023)

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates
por: Sader, Helio S, et al.
Publicado: (2017)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)

1284. Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam
por: Castanheira, Mariana, et al.
Publicado: (2021)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
por: Marino, Andrea, et al.
Publicado: (2023)

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients
por: Sader, Helio S, et al.
Publicado: (2021)

200. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against AmpC Hyperproducing Enterobacterales and P. aeruginosa Collected from United States (US) Medical Centers (2016-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

1443. Activity of Ceftazidime-Avibactam against Carbapemenase-negative Carbapenem-resistant Enterobacterales (CRE) Isolates from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2020)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2020)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
por: Gaibani, Paolo, et al.
Publicado: (2022)

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy
por: Arcari, Gabriele, et al.
Publicado: (2023)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

2427. Comparison of Ceftazidime–Avibactam and Ceftolozane-Tazobactam In Vitro Activities When Tested Against Gram-Negative Bacteria Isolated From Patients Hospitalized With Pneumonia in US Medical Centers (2017)
por: Sader, Helio S, et al.
Publicado: (2018)

2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021
por: Zilberberg, Marya D, et al.
Publicado: (2023)

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
por: Atkin, Stan D, et al.
Publicado: (2018)

250 Ceftazidime-avibactam Activity Tested Against a Large Collection of Enterobacteriaceae Isolates Collected in United States (USA) Hospitals in the 2011-2013 Period, Including Organisms Producing KPC- and CTX-M-variants
por: Castanheira, Mariana, et al.
Publicado: (2014)

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016–19)
por: Sader, Helio S, et al.
Publicado: (2021)

1590. Activity of Meropenem-Vaborbactam and Single-Agent Comparators against Enterobacterales Isolates Including KPC-Producing Isolates, from European Patients Hospitalized with Pneumonia Including Ventilator-Associated Pneumonia (2014-2019)
por: Shorttidge, Dee, et al.
Publicado: (2020)

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States (US) Medical Centers Stratified by Infection Type (2015–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

1684. Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016-2021)
por: Sader, Helio S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_13ih17oqs6vbc0ffaqbfj8sqds